A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH
Study Identifier:
ALXN2040-PNH-303
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Recruitment Complete
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: Danicopan
Date
Oct 2022 - Aug 2026
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A - N/A
Requirements Information
Sex
Female & Male
Age
N/A - N/A
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: Danicopan
Date
Oct 2022 - Aug 2026
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A - N/A years
Requirements Information
Protocol Summary
This is a single-arm long-term extension study that will enroll participants with PNH who have completed participation in Alexion-sponsored clinical studies with danicopan as an add on therapy to a C5i.
Trial Locations
Location
Status
Location
Research Site
Los Angeles, California, United States, 90089
Status
N/A
Location
Research Site
Chicago, Illinois, United States, 60612
Status
N/A
Location
Research Site
Baltimore, Maryland, United States, 21231
Status
N/A
Location
Research Site
Kansas City, Missouri, United States, 64111
Status
N/A
Location
Research Site
Long Island City, New York, United States, 11101
Status
N/A
Location
Research Site
Cleveland, Ohio, United States, 44195
Status
N/A